Table 1 Graphene-based nanosystem as a therapeutic carrier.
From: MIL-125-based nanocarrier decorated with Palladium complex for targeted drug delivery
Content | Features (nm) | Tumor type | Test type | Drug | Specious | Properties | Results | Refs | ||
|---|---|---|---|---|---|---|---|---|---|---|
In vitro | In vivo | Human Animal | ||||||||
GO/DOX/PEG-FA | 100 | Melanoma | B16F0 | Male C57BL/6 J and Mice | DOX | * | * | Photothermal, photodynamic therapy and fl-imaging | Tumor treatment upon NIR light activation | |
GO/NPs/PvP | 150 nm | Colorectaladeno carcinoma | Caco-2, HCT 116, NIH-3T3, HeLa, HEK-293 SCC-9 | DOX | * | pH sensitivity | Safe for normal cell and toxic for cancerous cell | |||
GO/AgNPs/Methotrexate | 20 nm | Breast | MCF-7, Hep-G2 | Methotrexate | * | Targeted therapy | Favorable particle size | |||
rGO/CuInS2/ZnS/liposome | 120 nm | Esophageal squamous carcinoma | Eca-109 | Mice | * | * | Photothermal, photodynamic therapy | CuInS2/ZnS nanocrystals converted the laser beam to the heat and prepared ROS in the cell and decreased the toxicity | ||
GO, GO/AgNPs, rGO, rGO/AgNPs | Lung | A549 | * | Antitumor activity | rGO/AgNPs more cytotoxic than other, IC50: 30 µg/ml | |||||
Graphene Quantum-dots | 65 nm | Dendritic cells | Immune response therapy | GQD can decrease the ROS creation | ||||||
GQDs/Biotin | 40 nm | A549 | DOX | * | Targeted delivery | Lower toxicity | ||||
